Visa (NYSE:V) and Augmedix (NASDAQ:AUGX) Head to Head Analysis

Visa (NYSE:VGet Free Report) and Augmedix (NASDAQ:AUGXGet Free Report) are both business services companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares Visa and Augmedix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Visa 54.72% 51.94% 21.66%
Augmedix -46.23% -182.36% -43.21%

Analyst Ratings

This is a breakdown of current ratings for Visa and Augmedix, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Visa 0 6 23 1 2.83
Augmedix 0 4 0 0 2.00

Visa presently has a consensus price target of $310.22, suggesting a potential upside of 14.97%. Augmedix has a consensus price target of $3.09, suggesting a potential upside of 31.94%. Given Augmedix’s higher possible upside, analysts plainly believe Augmedix is more favorable than Visa.

Institutional and Insider Ownership

82.2% of Visa shares are held by institutional investors. Comparatively, 87.1% of Augmedix shares are held by institutional investors. 0.2% of Visa shares are held by insiders. Comparatively, 11.0% of Augmedix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Visa has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Augmedix has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500.

Earnings & Valuation

This table compares Visa and Augmedix”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Visa $32.65 billion 15.06 $17.27 billion $8.95 30.15
Augmedix $44.85 million 2.58 -$19.17 million ($0.43) -5.44

Visa has higher revenue and earnings than Augmedix. Augmedix is trading at a lower price-to-earnings ratio than Visa, indicating that it is currently the more affordable of the two stocks.

Summary

Visa beats Augmedix on 12 of the 15 factors compared between the two stocks.

About Visa

(Get Free Report)

Visa Inc. operates as a payment technology company in the United States and internationally. The company operates VisaNet, a transaction processing network that enables authorization, clearing, and settlement of payment transactions. It also offers credit, debit, and prepaid card products; tap to pay, tokenization, and click to pay services; Visa Direct, a solution that facilitates the delivery of funds to eligible cards, deposit accounts, and digital wallets; Visa B2B Connect, a multilateral business-to-business cross-border payments network; Visa Cross-Border Solution, a cross-border consumer payments solution; and Visa DPS that provides a range of value-added services, including fraud mitigation, dispute management, data analytics, campaign management, a suite of digital solutions, and contact center services. The company also provides acceptance solutions, which include Cybersource that provides modular and value-added services for connecting merchants to payment processing; risk and identity solutions, such as Visa Advanced Authorization, Visa Secure, Visa Risk and Decision Manager, Visa Consumer Authentication Service, and payment-decisioning solutions for fraud prevention; and Visa Consulting and Analytics, a payment consulting advisory services. It provides its services under the Visa, Visa Electron, Interlink, V PAY, and PLUS brand names. The company serves merchants, financial institutions, and government entities. Visa Inc. was founded in 1958 and is headquartered in San Francisco, California.

About Augmedix

(Get Free Report)

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.

Receive News & Ratings for Visa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Visa and related companies with MarketBeat.com's FREE daily email newsletter.